Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial

Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial

Highlights•High-dose trivalent influenza vaccine is licensed for adults ≥65 years of age. •A quadrivalent formulation with antigen from both B lineages has been developed. •Adding the second B strain improved immunogenicity against the added strain. •Immunogenicity against the other strains remained...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2019-09, Vol.37 (39), p.5825-5834
Hauptverfasser: Chang, Lee-Jah, Meng, Ya, Janosczyk, Helene, Landolfi, Victoria, Talbot, H. Keipp
Format: Artikel
Sprache:eng
Schlagworte:
Active control
Adults
Age
Allergy and Immunology
Antibodies
Antigens
Clinical trial
Clinical trials
Drug dosages
Elderly adults
Exo-a-sialidase
Hemagglutination inhibition
High-dose influenza vaccine
Hospitalization
Immunization
Immunogenicity
Influenza
Laboratories
Licenses
Patient admissions
Pneumonia
Quadrivalent influenza vaccine
Safety
Seasons
Seroconversion
Vaccines
Virions
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights•High-dose trivalent influenza vaccine is licensed for adults ≥65 years of age. •A quadrivalent formulation with antigen from both B lineages has been developed. •Adding the second B strain improved immunogenicity against the added strain. •Immunogenicity against the other strains remained the same. •The vaccine’s tolerability was unaffected by adding the second B strain.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2019.08.016